Liothyronine sodium (T3)[ (Cytomel) ] Drug Information

Contains Liothyronine sodium (T3) drug information and provides Liothyronine sodium (T3) drug indication, contraindication, special concerns, side effects, overdose management and dosage
Search Drugs by Generic or Trade Name:
Browse Drugs by Generic Name:
[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z ]

List of Contents:
  • Indications
  • Contraindications
  • Special Concerns
  • Side Effects
  • Overdose Management
  • Dosage

  • Indications:
    No Available information
    Back to Top
    Use in children with cretinism because there is some question about whether the hormone crosses the blood-brain barrier.
    Back to Top
    Special Concerns:
    No Available information
    Back to Top
    Side Effects:
    No Available information
    Back to Top
    Overdose Management:
    No Available information
    Back to Top
    Drug Interactions:
    No Available information
    Back to Top
    Tablets Mild hypothyroidism.

    Adults, individualized, initial: 25 mcg/day. Increase by 12.5-25 mcg q 1-2 weeks until satisfactory response has been obtained. Usual maintenance: 25-75 mcg/day (100 mcg may be required in some clients). Use lower initial dosage (5 mcg/day) for the elderly, children, and clients with CV disease. Increase only by 5-mcg increments.


    Adults, initial: 5 mcg/day increased by 5-10 mcg/day q 1-2 weeks until 25 mcg/day is reached; then, increase q 1-2 weeks by 12.5-50 mcg. Usual maintenance: 50-100 mcg/day.

    Simple (nontoxic) goiter.

    Adults, initial: 5 mcg/day; then, increase q 1-2 weeks by 5-10 mcg until 25 mcg/day is reached; then, dose can be increased by 12.5-25 mcg/week until the maintenance dose of 50-100 mcg/day is reached (usual is 75 mcg/day).

    T3 suppression test.

    75-100 mcg/day for 7 days followed by a repeat of the I131 thyroid uptake test (a 50% or greater suppression of uptake indicates a normal thyroid-pituitary axis).

    Congenital hypothyroidism.

    Adults and children, initial: 5 mcg/day; then, increase by 5 mcg/day q 3-4 days until the desired effect is achieved. Approximately 20 mcg/day may be sufficient for infants a few months of age while children 1 year of age may require 50 mcg/day. Children above 3 years may require the full adult dose.

    IV Only Myxedema coma, precoma.

    Adults, initial: 25-50 mcg. Base subsequent doses on continuous monitoring of client's clinical status and response. Doses should be given at least 4 hr, and no more than 12 hr, apart. Total daily doses of 65 mcg in initial days of therapy are associated with a lower incidence of mortality. In cases of known CV disease, give an initial dose of 10-20 mcg.
    Back to Top